Hydra Biosciences and Boehringer Ingelheim have entered into a worldwide research collaboration and license agreement to identify small-molecule TRP inhibitors, with a primary focus on the treatment of renal diseases and disorders.
Under the terms of the collaboration agreement, the companies will work together to identify and advance candidate inhibitors.
|Searching for more deal information? Current Partnering offers the following options:|
Boehringer Ingelheim is responsible for the global development and commercialization of the inhibitors that come from the collaboration.
Hydra will receive an undisclosed upfront payment, additional research funding, and the Company is eligible to receive milestone payments and tiered royalty payments on future product sales.
For further deal information visit Current Agreements (subscription required)
Scorecard: Top partnering deals by value in 2015
View: Top biotech companies